Novavax, a clinical-stage biotechnology company, recently announced a purchase agreement with the Serum Institute of India (SII) to manufacture and distribute its COVID-19 vaccine candidate, NVX-CoV2373. This agreement is a critical milestone in the fight against the COVID-19 pandemic, as it expands the global supply of vaccines and increases access to those in need.
Under the terms of the agreement, Novavax will license its vaccine technology to SII for production and distribution primarily in low- and middle-income countries, including India. Novavax and SII will also work together to seek regulatory approval for the vaccine in these countries. This partnership is expected to yield over 1 billion doses of NVX-CoV2373 annually, significantly increasing the global supply of vaccines.
NVX-CoV2373 is an adjuvanted protein subunit vaccine that targets the SARS-CoV-2 spike protein. In clinical trials, the vaccine has demonstrated an overall efficacy of 90.4% against symptomatic COVID-19 and 100% efficacy against severe disease. Additionally, the vaccine has shown promising efficacy against emerging variants of the virus, providing an extra layer of protection against the evolving pandemic.
Novavax`s partnership with SII is not only a critical step in the fight against COVID-19 but also a testament to the power of global collaboration in advancing public health. By leveraging Novavax`s technology and SII`s production capabilities, this partnership has the potential to make a significant impact on the global vaccine supply and help bring an end to the pandemic.
In conclusion, Novavax`s purchase agreement with the Serum Institute of India represents a significant milestone in the global fight against COVID-19. This partnership expands the global supply of vaccines and increases access to those in need, particularly in low- and middle-income countries. With the vaccine`s promising efficacy and the partnership`s scale, this agreement is a crucial step towards ending the pandemic and restoring normalcy to our communities.